Post PCI Antiplatelet Strategy Selection Tool

Clinical calculation support · Verify results before clinical use

Clinical assessment

Enter the current post-PCI context to review antiplatelet strategy considerations.

Use time since the most recent PCI relevant to the current episode. Enter 0 for the immediate post-procedure period.
Use a structured assessment (for example, ARC-HBR criteria) rather than an unsupported impression where possible.
Consider recurrent ischemia, prior stent thrombosis, complex PCI, and extent of coronary disease.

Clinical context

Antithrombotic treatment after PCI should balance recurrent ischemic events and stent thrombosis against bleeding. This tool organizes selected factors; it does not calculate a validated risk score or prescribe a drug regimen.

General principles

  • For ACS patients without high bleeding risk, DAPT with aspirin plus an oral P2Y12 inhibitor for at least 12 months is the default strategy.
  • Selected patients may benefit from a bleeding-reduction strategy, including P2Y12-inhibitor monotherapy or abbreviated DAPT, depending on the agent, timing, clinical stability, and guideline criteria.
  • When long-term oral anticoagulation is indicated, minimize triple-therapy exposure; the duration of aspirin and the subsequent regimen depend on individual ischemic and bleeding risks.
  • Beyond 12 months, consider extended antithrombotic therapy only after explicit individualized assessment and shared decision-making.

Important limitations

The inputs “high bleeding risk” and “high ischemic risk” are broad categories and are not independently validated by this tool. It does not account for every drug contraindication, dose adjustment, adherence issue, stent characteristic, procedural complication, or patient preference.

Guideline references

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
J Am Coll Cardiol. DOI: 10.1016/j.jacc.2024.11.009

2023 ESC Guidelines for the management of acute coronary syndromes.
Eur Heart J. DOI: 10.1093/eurheartj/ehad191

Urban P, et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium.
Circulation. 2019. DOI: 10.1161/CIRCULATIONAHA.119.040167

Clinical disclaimer: This tool is intended for healthcare professionals as a decision-support aid, not as a substitute for clinical judgment, current guideline review, or local protocols. Do not stop or change antiplatelet or anticoagulant therapy solely on the basis of this output. Very early interruption after PCI can be hazardous; urgent bleeding or surgery requires individualized specialist assessment.